On January 14, the Department of Health & Human Services’ (HHS) released the 2022 Notice of Benefit and Payment Parameters (NBPP) final rule. Several provisions of the final rule promote access to insurance options that do not provide adequate coverage for medicines, including short-term limited duration insurance. Last month, PhRMA submitted comments on the HHS 2022 NBPP proposed rule expressing concern about these policies, as well as parts of the proposed rule that reflect HHS’s continued misunderstanding of the role that manufacturer cost-sharing assistance plays in helping patients pay for the out-of-pocket costs of their medicines.
